Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
JAGX
JAGUAR HEALTH, INC.
NASDAQ
$4.73
▲ UP 29.23% (1.07)

KEY STATISTICS

Market Cap$2.06 M
52w High$1267.88
52w Low$2.35
Dividend Yield—
Frequency—
P/E-0.11
Volume15.73M
Shares Out.434.13K

COMPANY

LEADERSHIP

Lisa A. Conte
CHIEF EXECUTIVE
Lisa A. Conte

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 12, 2015
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
47

PRICE TARGET

Target High$3.21
Target Low$3.21
Target Median$3.21
Target Consensus$3.21

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.$4.85M
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2026-09-17Reverse1:15
2026-04-30Reverse1:35
2025-03-24Reverse1:25
2024-05-23Reverse1:60
2023-01-23Reverse1:75
2021-09-08Reverse1:3
2019-06-07Reverse1:70
2018-06-01Reverse1:15

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00%
1.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
83.01%
HOLDERS
17
TOP 8 OF 17 · RANKED BY POSITION SIZE
Ubs Group AG
112.9K sh
$41.77K
Geode Capital Management, LLC
110.1K sh
$40.8K
Drw Securities, LLC
91.0K sh
$211.96K
Hrt Financial LP
15.2K sh
$5K
Two Sigma Securities, LLC
12.6K sh
$4.65K
Xtx Topco Ltd
12.5K sh
$11.59K
Tower Research Capital LLC (Trc)
3.6K sh
$3.36K
Sbi Securities Co., Ltd.
2.6K sh
$953

PRICE

$4.73 ▲ UP 29.23% (+$1.07)
OVERLAYS
$4.50$5.00$5.509:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM4.73

About Jaguar Health, Inc.

https://jaguar.health ↗

Jaguar Health, Inc. develops prescription medicines for gastrointestinal distress in humans and animals, including Mytesi, Crofelemer, and Canalevia, targeting conditions like diarrhea in HIV, cancer, infants, and dogs.

INDUSTRY

Biotechnology

A PRODUCT JAGUAR HEALTH, INC. IS KNOWN FOR

Mytesi (crofelemer)
Mytesi (crofelemer)

Mytesi, an FDA-approved prescription for non-infectious diarrhea in adults with HIV/AIDS, is Jaguar Health's key product, generating significant revenue and recently expanded through a January 2026 partnership to enhance U.S. marketing and manufac...

COMPETITORS

COMPETITOR
ABBV COMPARE
BHC COMPARE
IRWD COMPARE
PFE COMPARE
RDHL COMPARE

Jaguar Health in 2025

SENTIMENT: + POSITIVE
Mohamad Miqdady
REGULATORY · DECEMBER 2025

Jaguar Health Announces Positive Early Results for Crofelemer in Infants with Rare Disease and FDA Discussions for Expedited Approval

In December 2025, Jaguar Health announced initial results from an investigator-initiated proof-of-concept trial showing that its drug, crofelemer, could potentially extend the lives of infants with microvillus inclusion disease (MVID), a rare and life-threatening condition with no approved treatments. The company reported a significant reduction in the need for total parenteral support and confirmed it had met with the FDA in October 2025 to discuss a potential expedited approval pathway.

Latest News

ACCESSWIRE · OCT 2, 2026

Jaguar Health Announces a Special Stock Dividend

Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic alternatives SAN FRANCISCO, CA / ACCESS Newswire / October 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock and certain outstanding warrants as of record on October 13, 2026. The Special Stock Dividend will consist of the Company's Series R Convertible Preferred Stock (the "Preferred Stock").

READ ARTICLE
EARLIER COVERAGE
ACCESSWIRE · SEP 29, 2026

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS-IF for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026). ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.

READ ARTICLE

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

SECTORS PEERS

PEERPRICE
KZIA$9.42COMPARE
CNSP$5.40COMPARE
INM$1.33COMPARE
SXTP$1.50COMPARE
GRI$1.92COMPARE
SILO$1.42COMPARE
GNPX$2.77COMPARE
BDRX$0.61COMPARE

INSIDER TRADES

★
DIRECTOR
MICEK JOHN
Purchase · 7.4K shares
2025-12-11
★
DIRECTOR
MICEK JOHN
Purchase · 7.4K shares
2025-12-11
★
OFFICER: SEE REMARKS
Wolin Jonathan S.
Purchase · 11.7K shares
2025-12-11
★
OFFICER: SEE REMARKS
Wolin Jonathan S.
Purchase · 11.7K shares
2025-12-11